Non-small cell lung carcinoma: current treatment strategies and emerging challenges
Abstract
The most prevalent cause of death linked to cancer in the lungs is still lung cancer. Lung cancer specifically the non-small cell lung cancer (NSCLC) is a form of lung cancer which is widely common around 85% of all lung cancer patients are diagnosed with NSCLC. NSCLC also is further classified into multi histological subtypes which are adenocarcinomas, squamous cells carcinoma, large cell carcinoma, and mixed. The treatment of NSCLC relies heavily on systemic chemotherapy using platinum based drug.AN When treating NSCLC, a number of techniques and challenges are involved. These methodologies include targeted therapy, immunotherapy, or the combination of both, with the goal of targeting and inhibiting certain molecular pathways, or expanding the extent of the patient’s defence response. In treating NSCLC, this is one of the biggest issues. Targeted therapies were designed to improve NSCLC therapeutics, however, it has proven difficult due to early emergence of resistance. Resistance mechanisms including targeted drug resistance development and trait variations including gene mutations and anomalies specific for each NSCLC subtype Relative differences in the amount of NSCLC there is also explains the reasons why treatment targeting each NSCLC subtype is difficult. In addition to this, the age and sex of the patient will play a significant role in making treatment decisions as well as the outcomes of the NSCLC treatment in this study. To conclude, a synopsis of the various approaches being used in tackling NSCLC and the corresponding difficulties including that of each type of therapy has been presented.
Keywords:
Non-small cell carcinoma, NSCLC, Targeted therapy, Immunotherapy, KRAS mutationDOI
https://doi.org/10.25004/IJPSDR.2025.170112References
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014 Jan;64(1):9-29.
Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ. American Cancer Society guidelines for the early detection of cancer. CA: a cancer journal for clinicians. 2009 Feb; 52(1):8-22. doi: 10.3322/canjclin.52.1.8
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2024 May;74(3):229-63.
Kowalczyk A, Jassem J. Multidisciplinary team care in advanced lung cancer. Translational Lung Cancer Research. 2020 Aug;9(4):1690.
eiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nature reviews Clinical oncology. 2023 Sep;20(9):624-39.
Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers–a review. European journal of cancer. 2012 Jun 1;48(9):1299-311. doi: 10.1016/j.ejca.2012.03.007
Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Comparison of aspects of smoking among the four histological types of lung cancer. Tobacco control. 2008 Jun 1;17(3):198-204. doi: 10.1136/tc.2007.022582
Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new world health organization classification of lung tumours. PULMONOLOGIYA. 2004(6):11-21. doi: 10.1183/09031936.01.00275301
Rossi A, Sacco PC, Santabarbara G, Sgambato A, Casaluce F, Palazzolo G, Maione P, Gridelli C. Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. Expert Opinion on Pharmacotherapy. 2017 Jan 22;18(2):151-63. doi: 10.1080/14656566.2017.1280460
Tanoue LT, Detterbeck FC. New TNM classification for non-small-cell lung cancer. Expert review of anticancer therapy. 2009 Apr 1;9(4):413-23. doi: 10.1586/era.09.11
Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiation oncology. 2014 Dec;9:1-8. doi: 10.1186/1748-717X-9-210
van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. Journal of Thoracic Oncology. 2015 May 1;10(5):826-31. doi:10.1097/JTO.0000000000000483
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J. Stereotactic body radiation therapy for inoperable early stage lung cancer. Jama. 2010 Mar 17;303(11):1070-6. doi: 10.1001/jama.2010.261
Fakiris, A.J., McGarry, R.C., Yiannoutsos, C.T., Papiez, L., Williams, M., Henderson, M.A. and Timmerman, R., 2009. Stereotactic body radiation therapy for early-stage non–small-cell lung carcinoma: four-year results of a prospective phase II study. International Journal of Radiation Oncology* Biology* Physics, 75(3), pp.677-682. doi: 10.1016/j.ijrobp.2008.11.042
Lynch, T.J., Patel, T., Dreisbach, L., McCleod, M., Heim, W.J., Hermann, R.C., Paschold, E., Iannotti, N.O., Dakhil, S., Gorton, S. and Pautret, V., 2010. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non–small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. Journal of Clinical Oncology, 28(6), pp.911-917. doi: h 10.1200/JCO.2009.21.9618
Sculier JP. Anticancer treatment for advanced non-small cell lung cancer. Breathe. 2011 Dec 1;8(2):124-33. doi: 10.1183/20734735.005011
Gv S. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. InProc ASCO 2001 (Vol. 308). doi: 10.1200/JCO.2002.02.068
Kelly, K., Crowley, J., Bunn Jr, P.A., Presant, C.A., Grevstad, P.K., Moinpour, C.M., Ramsey, S.D., Wozniak, A.J., Weiss, G.R., Moore, D.F. and Israel, V.K., 2001. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. Journal of Clinical Oncology, 19(13), pp.3210-3218. doi: 10.1200/JCO.2001.19.13.3210
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. New England Journal of Medicine. 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954
Fossella, F., Pereira, J.R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K.V., Ramlau, R., Szczesna, A., Fidias, P. and Millward, M., 2003. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non–small-cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology, 21(16), pp.3016-3024. doi: 10.1200/JCO.2003.12.046
Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines. Chest. 2007 Sep 1;132(3):234S-42S. doi: 10.1378/chest.07-1378
Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung cancer. 2010 Mar 1;67(3):257-74. doi: 10.1016/j.lungcan.2009.10.012
Araghi M, Mannani R, Heidarnejad maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell International. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y
Zhou J. Advances and prospects in cancer immunotherapy. New Journal of Science. 2014;2014(1):745808. doi: 10.1155/2014/745808
Paulsen EE, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, Busund LT, Bremnes RM, Donnem T. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunology, Immunotherapy. 2017 Nov;66:1449-61. doi: 10.1007/s00262-017-2039-2
Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F. Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations. International journal of molecular sciences. 2021 Jun 11;22(12):6288. doi: 10.3390/ijms22126288
Borghaei H, Gettinger S, Vokes EE, Chow LQ, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C. Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer. Journal of Clinical Oncology. 2021 Mar 1;39(7):723-33. doi: 10.1200/JCO.20.01605
Barlesi F, Garon EB, Kim DW, Enriqueta F, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G, Surmont V. Health-related quality of life in KEYNOTE-010: a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC. Journal of Thoracic Oncology. 2019;14(7):1306. doi: 10.1016/j.jtho.2019.01.016
Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M. KEYNOTE-024 5-year OS update: First-line pembrolizumab vs platinum-based chemotherapy in patients with metastatic non–small-cell lung cancer and PD-L1 tumor proportion score≥ 50%. Ann Oncol. 2020 Sep 19;31(suppl 4):S1142-215. doi: 10.1200/JCO.21.00174
Mizuno T, Katsuya Y, Sato J, Koyama T, Shimizu T, Yamamoto N. Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Frontiers in Oncology. 2022 Aug 26;12:925938. doi: 10.3389/fonc.2022.925938
Suraya R, Tachihara M, Nagano T, Nishimura Y, Kobayashi K. Immunotherapy in advanced non-small cell lung cancers: Current status and updates. Cancer Management and Research. 2022 Jun 22:2079-90. doi: 10.2147/CMAR.S366738
Ilie M, Hofman P. Atezolizumab in advanced non-small cell lung cancer. Journal of thoracic disease. 2017 Oct;9(10):3603. doi: 10.21037/jtd.2017.09.73
Xie Q, Zheng H, Su N, Li Q. Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China. BMJ open. 2022 Aug 1;12(8):e061592. doi: 10.1136/bmjopen-2022-061592
Liang H, Chen Q, Hu Z, Zhou L, Meng Q, Zhang T, Wang B, Ge Y, Lu S, Ding W, Zhou X. Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis. Annals of Translational Medicine. 2022 Mar;10(6). doi: 10.21037/atm-22-764
Ye H, Zhao J, Xu X, Zhang D, Shen H, Wang S. Role of adenosine A2a receptor in cancers and autoimmune diseases. Immunity, Inflammation and Disease. 2023 Apr;11(4):e826. doi: 10.1002/iid3.826
Garcia-Lorenzo E, Moreno V. Targeting the adenosine 2A receptor in non-small cell lung cancer: shooting with blank bullets?. Translational Lung Cancer Research. 2023 Apr 4;12(4):653. doi: 10.21037/tlcr-23-38
Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. Current landscape of immunotherapy trials involving the programmed cell death protein 1/programmed death-ligand 1 axis in intrathoracic tumors. JTO Clinical and Research Reports. 2021 Apr 1;2(4):100149. doi: 10.1016/j.jtocrr.2021.100149
Zhang H, Li M, Kaboli PJ, Ji H, Du F, Wu X, Zhao Y, Shen J, Wan L, Yi T, Wen Q. Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy. The International journal of biological markers. 2021 Jun;36(2):22-32. doi: 10.1177/1724600821100547
Djureinovic D, Wang M, Kluger HM. Agonistic CD40 Antibodies in Cancer Treatment. Cancers 2021, 13, 1302 [Internet]. 2021. doi: 10.3390/cancers13061302
Nicolson M. ES05. 01 lung cancer survival: progress and challenges. Journal of Thoracic Oncology. 2019 Oct 1;14(10):S24. doi: 10.1016/j.jtho.2019.08.087
Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacological reviews. 2012 Jul 1;64(3):706-21. doi: 10.1124/pr.111.005637
Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. World journal of clinical oncology. 2016 Feb 2;7(1):106. doi: 10.5306/wjco.v7.i1.106
Mariani M, Karki R, Spennato M, Pandya D, He S, Andreoli M, Fiedler P, Ferlini C. Class III β-tubulin in normal and cancer tissues. Gene. 2015 Jun 1;563(2):109-14. doi:10.1016/j.gene.2015.03.061
Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003 Oct;22(47):7280-95. doi: 10.1038/sj.onc.1206934
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer drug resistance. 2019;2(2):141. doi: 10.20517/cdr.2019.10
Zhang Y, Yang SH, Guo XL. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer. Biomedicine & pharmacotherapy. 2017 Dec 1;96:659-66. doi: 10.1016/j.biopha.2017.10.041
Lagas JS, Fan L, Wagenaar E, Vlaming ML, van Tellingen O, Beijnen JH, Schinkel AH. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clinical cancer research. 2010 Jan 1;16(1):130-40. doi: 10.1158/1078-0432.CCR-09-1321
Ashrafizadeh, M., Mirzaei, S., Hashemi, F., Zarrabi, A., Zabolian, A., Saleki, H., Sharifzadeh, S.O., Soleymani, L., Daneshi, S., Hushmandi, K. and Khan, H., 2021. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomedicine & Pharmacotherapy, 141, p.111824. doi: 10.1016/j.biopha.2021.111824
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015 Nov 26;527(7579):525-30. doi: 10.1038/nature16064
Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC cancer. 2012 Dec;12:1-0. doi: 10.1186/1471-2407-12-91
Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget. 2015 Oct 10;6(32):34014. doi: 10.18632/oncotarget.5607
Beganoyic S. Clinical significance of the KRAS mutation. Bosnian journal of basic medical sciences. 2009 Oct;9(Suppl 1):S17. doi: 10.17305/bjbms.2009.2749
Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M. Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance. Cancers. 2022 Mar 4;14(5):1321. doi: 10.3390/cancers14051321
Błach J, Wojas-Krawczyk K, Nicoś M, Krawczyk P. Failure of immunotherapy—the molecular and immunological origin of immunotherapy resistance in lung cancer. International Journal of Molecular Sciences. 2021 Aug 21;22(16):9030. doi: 10.3390/ijms22169030
Zhao LP, Hu JH, Hu D, Wang HJ, Huang CG, Luo RH, Zhou ZH, Huang XY, Xie T, Lou JS. Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. Biomedicine & Pharmacotherapy. 2022 Jun 1;150:112949. doi: 10.1016/j.biopha.2022.112949
Lennox L, Lambe K, Hindocha CN, Coronini-Cronberg S. What health inequalities exist in access to, outcomes from and experience of treatment for lung cancer? A scoping review. BMJ open. 2023 Nov 1;13(11):e077610. doi: 10.1136/bmjopen-2023-077610
Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct 1;124:298-309. doi: 10.1016/j.lungcan.2018.07.042
Ihbe-Heffinger A, Paessens BJ, von Schilling C, Shlaen M, Gottschalk N, Berger K, Bernard R, Kiechle M, Peschel C, Jacobs VR. Management of febrile neutropenia–a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Oncology Research and Treatment. 2011 Apr 26;34(5):241-6. doi: 10.1159/000327711
Ma LR, Li JX, Tang L, Li RZ, Yang JS, Sun A, Leung EL, Yan PY. Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions. Oncology Letters. 2021 Nov;22(5):787. doi: 10.3892/ol.2021.13048
Asukai Y, Valladares A, Camps C, Wood E, Taipale K, Arellano J, Cassinello A, Sacristán JA, Dilla T. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC cancer. 2010 Dec;10:1-4. doi: 10.1186/1471-2407-10-26
Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L. Distance as a barrier to cancer diagnosis and treatment: review of the literature. The oncologist. 2015 Dec 1;20(12):1378-85. doi: 10.1634/theoncologist.2015-0110
Haik Y, Bantekas I. Nano-drug Clinical Trials: Informed Consent and Risk Management Through Blockchain. Pitt. J. Tech. L. & Pol'y. 2020;21:35. doi: 10.5195/tlp.2021.243
Published
Abstract Display: 147 
PDF Downloads: 102 How to Cite
Issue
Section
Copyright (c) 2025 Swati K. Kurtkoti, Harshaben V. Patel
This work is licensed under a Creative Commons Attribution 4.0 International License.
